IMDX
What one share of Insight Molecular Diagnostics holds
In Vitro and In Vivo Diagnostic Substances
We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category.
Insight Molecular Diagnostics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$1.46 |
| Capex (buildings and equipment) | $0.12 |
| Free cash flow | −$0.92 |
| Cash and investments | $0.54 |
| Book value | −$0.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$8.42 | $0.08 | −$5.75 | — | $6.86 |
| 2017 | — | −$12.83 | $0.06 | −$8.93 | — | $2.80 |
| 2018 | — | −$8.32 | $0.02 | −$6.17 | — | $1.68 |
| 2019 | — | −$8.74 | $0.36 | −$8.04 | — | $10.81 |
| 2020 | $0.37 | −$9.14 | $0.37 | −$8.31 | — | $9.69 |
| 2021 | $0.49 | −$14.42 | $0.51 | −$8.59 | — | $14.14 |
| 2022 | $0.17 | −$13.25 | $0.78 | −$9.01 | — | $5.78 |
| 2023 | $0.20 | −$3.75 | $0.04 | −$3.09 | — | $2.48 |
| 2024 | $0.14 | −$4.66 | $0.04 | −$1.62 | — | −$0.70 |
| 2025 | $0.13 | −$1.65 | $0.10 | −$0.83 | — | −$1.10 |